Cell-type Specific Delivery
Cell-type Specific Delivery - Related Videos
13:47
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
0 Views •
Cited by 36 •
2011
Several 2’-Fluoro RNA aptamers against HIV-1Ba-L gp120 with nanomole affinity are isolated from a RNA library by in vitro SELEX procedure. A new dual inhibitory function anti-gp120 aptamer-siRNA chimera is created and shows considerable promise for systemic anti-HIV therapy.
09:31
Heterokaryon Technique for Analysis of Cell Type-specific Localization
0 Views •
Cited by 1 •
2011
A flexible and efficient method for the characterization of cell type-specific protein localization and nucleocytoplasmic shuttling is described. This heterokaryon approach uses fluorescently-labeled fusion proteins to image protein localizations after cell fusion. The protocol is amenable to steady-state localizations or more dynamic determinations based on live cell imaging.
11:19
Fabrication of Extracellular Matrix-derived Foams and Microcarriers as Tissue-specific Cell Culture and Delivery Platforms
0 Views •
Cited by 26 •
2017
The tissue-specific extracellular matrix (ECM) is a key mediator of cell function. This article describes methods for synthesizing pure ECM-derived foams and microcarriers that are stable in culture without the need for chemical crosslinking for applications in advanced 3D in vitro cell culture models or as pro-regenerative bioscaffolds.
03:11
Recombinant Adeno Associated Virus Based Gene Delivery: A Technique for Transgene Delivery and Cardiac-Specific Expression in Rodent Model
0 Views •
2025
In this video, we demonstrate recombinant adeno associated virus-based gene delivery in the mouse pup. This method helps in studying gene expression in the targeted cells.
01:27
Insulin Formulations: Types and Delivery
0 Views •
2024
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection. Short-acting insulins are divided into rapid-acting...
FAQs
Efficiency depends on more than choosing a recognizable target. Receptor abundance can affect how much of a delivery system binds and enters a cell, while tissue barriers can restrict access before binding occurs. These variables help explain why the same cargo may reach different cell populations unevenly and why selectivity does not guarantee uniform delivery.
Targeting ligands, antibodies, and engineered delivery vehicles provide different ways to connect cargo with a cell-surface receptor. Their shared function is recognition followed by binding and uptake, but the selected component determines how the cargo is presented to the target. Comparing these options is important when adapting delivery to immune cells, infected cells, or pathogen-associated targets.
Intracellular release is a separate requirement from cell binding. A payload can recognize a receptor and be taken up, yet its effect depends on release inside the selected cell. This distinction matters for therapeutic, vaccine, or genetic cargo because successful targeting must be evaluated across the sequence of recognition, uptake, and intracellular availability.
A practical design workflow starts by selecting the intended cell population and cargo, then pairing that cargo with a ligand, antibody, or engineered vehicle that can recognize a relevant surface receptor. Researchers must also consider receptor abundance and tissue barriers. The resulting system can then be examined for selective binding, uptake, and intracellular release.
In immunology and infection research, cell-type specific delivery can direct interventions toward immune cells, infected cells, or pathogen-associated targets. This focus supports investigations of immune signaling and host-pathogen interactions, while also informing vaccine design and precision treatment development. Its value lies in connecting a chosen cellular target with a defined research or therapeutic objective.
The approach can improve the relationship between desired activity and unwanted exposure, because limiting delivery to other tissues may reduce off-target effects. However, outcomes remain influenced by access barriers and receptor abundance. Interpreting results therefore requires distinguishing selective targeting from overall delivery efficiency, since strong performance in one cell population may not extend across tissues.